

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NO: 52, 74, 83 and 1541-38, 42-204, 205, 207, 210-290, 293, 296, 297 and 300;

(b) complements of the sequences provided in SEQ ID NO: 52, 74, 83 and 1541-38, 42-204, 205, 207, 210-290, 293, 296, 297 and 300;

(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO: 52, 74, 83 and 1541-38, 42-204, 205, 207, 210-290, 293, 296, 297 and 300;

(d) sequences that hybridize to a sequence provided in SEQ ID NO: 52, 74, 83 and 1541-38, 42-204, 205, 207, 210-290, 293, 296, 297 and 300, under moderately stringent conditions;

(e) sequences having at least 75% identity to a sequence of SEQ ID NO: 52, 74, 83 and 1541-38, 42-204, 205, 207, 210-290, 293, 296, 297 and 300;

(f) sequences having at least 90% identity to a sequence of SEQ ID NO: 52, 74, 83 and 1541-38, 42-204, 205, 207, 210-290, 293, 296, 297 and 300; and

(g) degenerate variants of a sequence provided in SEQ ID NO: 52, 74, 83 and 1541-38, 42-204, 205, 207, 210-290, 293, 296, 297 and 300.

2. (Canceled)

3. (Original) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. (Original) A host cell transformed or transfected with an expression vector according to claim 3.

5.-7. (Canceled)

8. (Currently Amended) An oligonucleotide that hybridizes to a sequence recited in SEQ ID NO: ~~52, 74, 83 and 154-138, 42-204, 205, 207, 210-290, 293, 296, 297 and 300~~ under moderately stringent conditions.

9.-10. (Canceled)

11. (Currently Amended) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) a polynucleotides according to claim 1;
- (c) antibodies according to claim 5;
- (d) fusion proteins according to claim 7;
- (e) T cell populations according to claim 10; and
- (f) antigen presenting cells that express a polypeptide according to claim 2.

12.-14. (Canceled)

15. (Original) A diagnostic kit comprising at least one oligonucleotide according to claim 8.

16.-17. (Canceled)